Geoffrey Greene to Mutation
This is a "connection" page, showing publications Geoffrey Greene has written about Mutation.
Connection Strength
0.436
-
Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Mol Cancer Res. 2021 09; 19(9):1559-1570.
Score: 0.090
-
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499.
Score: 0.051
-
Modulation of alphaCaMKII signaling by rapid ERalpha action. Brain Res. 2008 Jul 30; 1222:1-17.
Score: 0.037
-
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol. 2008 Apr; 4(4):241-7.
Score: 0.036
-
An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008 Jun; 149(6):2970-9.
Score: 0.036
-
Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line. Biophys J. 2022 10 04; 121(19):3651-3662.
Score: 0.024
-
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 05 16; 11.
Score: 0.024
-
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54.
Score: 0.023
-
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
Score: 0.019
-
Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chem Biol. 2018 12 21; 13(12):3374-3384.
Score: 0.019
-
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018 06; 18(6):377-388.
Score: 0.018
-
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017 03; 7(3):277-287.
Score: 0.017
-
Prolactin activates ERa in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology. 2013 Dec; 154(12):4483-92.
Score: 0.013
-
Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS One. 2013; 8(5):e64091.
Score: 0.013
-
Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004 Dec; 18(12):2854-65.
Score: 0.007
-
The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202.
Score: 0.003
-
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6.
Score: 0.003
-
A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. Mol Endocrinol. 1988 Jan; 2(1):14-21.
Score: 0.002